Abstract
Excessive bodyweight gain was reported during the 1950s as an adverse effect of typical antipsychotic drug treatment, but the magnitude of bodyweight gain was found to be higher with the atypical antipsychotic drugs that were introduced after 1990. Clozapine and olanzapine produce the greatest bodyweight gain, ziprasidone and aripiprazole have a neutral influence, and quetiapine and risperidone cause an intermediate effect. In the CATIE study, the percentage of patients with bodyweight gain of >7% compared with baseline differed significantly between the antipsychotic drugs, i.e. 30%, 16%, 14%, 12% and 7% for olanzapine, quetiapine, risperidone, perphenazine (a typical antipsychotic) and ziprasidone, respectively (p < 0.001).
Appetite stimulation is probably a key cause of bodyweight gain, but genetic polymorphisms modify the bodyweight response during treatment with atypical antipsychotics.
In addition to nutritional advice, programmed physical activity, cognitive-behavioural training and atypical antipsychotic switching, pharmacological adjunctive treatments have been assessed to counteract excessive bodyweight gain. In some clinical trials, nizatidine, amantadine, reboxetine, topiramate, sibutramine and metformin proved effective in preventing or reversing atypical antipsychotic-induced bodyweight gain; however, the results are inconclusive since few randomized, placebo-controlled clinical trials have been conducted. Indeed, most studies were short-term trials without adequate statistical power and, in the case of metformin, nizatidine and sibutramine, the results are contradictory. The tolerability profile of these agents is adequate.
More studies are needed before formal recommendations on the use of these drugs can be made. Meanwhile, clinicians are advised to use any of these adjunctive treatments according to their individual pharmacological and tolerability profiles, and the patient’s personal and family history of bodyweight gain and metabolic dysfunction.
Similar content being viewed by others
References
Caffey Jr EM. Experiences with large scale interhospital cooperative research in chemotherapy. Am J Psychiatry 1961; 117(2): 713–9
Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995; 21(3): 463–72
Baptista T, Araujo de Baptista E, NMK Ng Ying Kin, et al. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35: 205–19
Keltner NL, Johnson V. Biological perspectives. Aripiprazole: a third generation of antipsychotics begins? Perspect Psychiatr Care 2002; 38(4): 157–9
McEvoy JP, Lieberman JA, Stroup TS. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163(4): 600–10
Kerwin RW, Bolonna AA. Is clozapine antisuicidal? Expert Rev Neurother 2004; 4(2): 187–90
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. N Engl J Med 2005; 353: 1209–23
Green A, Patel J, Goisman R, et al. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000; 22: 224–35
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65(2): 267–72
Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007; (1): CD005148
Bray GA, Greenway FL. Current and potential drugs for treatment of drugs for treatment of obesity. Endocr Rev 1999; 20: 805–75
Meguid MM, Fetissiv SO, Varma M, et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 2000; 16: 843–57
Mystkowski P, Schwartz MW. Gonadal steroids and energy homeostasis in the leptin era. Nutrition 2000; 16: 937–46
Schneider JE. Energy balance and reproduction. Physiol Behav 2004; 81: 289–317
Asarian L, Geary N. Modulation of appetite by gonadal steroid hormones. Philos Trans R Soc London B Biol Sci 2006; 316: 1251–63
Baptista T, LaCruz A, Meza T, et al. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiat 2001; 46: 829–34
Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96
Taylor DM. McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 2000; 101: 416–32
Wetterling T. Body weight gain with atypical antipsychotics: a comparative review. Drug Saf 2001; 24: 59–73
McIntyre RS, Trakas K, Lin D, et al. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National outcomes measurement study in schizophrenia. Can J Psychiatry 2003; 48: 689–94
Brecher M, Leong RW, Stening G, et al. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry 2007; 68(4): 597–603
Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681–90
McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the reatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164(7): 1050–60
McEvoy JP, Daniel DG, Carson Jr WH, et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007; 41(11): 895–905
Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 2006; 29(4): 303–19
Koga M. Clinical factors related to gains in body mass index (BMI) among patients under long-term antipsychotic treatment. Seishin Shinkeigaku Zasshi 2003; 105(4): 473–88
Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004; 161(8): 1324–33
Bai YM, Lin CC, Chen JY, et al. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006; 163(7): 1276–9
Basson BR, Kinon BJ, Taylor CC. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001; 62(4): 231–8
Ascher-Svanum H, Stensland M, Zhao Z, et al. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 2005; 5: 3–16
Beasley Jr CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997; 58Suppl. 10: S13–7
Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92–100
Perry PJ, Argo TR, Carnahan RM, et al. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol 2005; 25(3): 250–4
Cohen S, Glazewski R, Khan S, et al. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. Clin Psychiatry 2001; 62(2): 114–6
Lane HY, Chang YC, Cheng YC, et al. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry 2003; 64(3): 316–20
Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975–81
Martin A, Landau J, Leebens P, et al. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 2000; 10: 259–68
Kasper S, Müller-Spanh F. Review of quetiapine and its clinical applications in schizophrenia. Exp Opin Pharmacother 2000; 1: 783–801
Buse J, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003; 56: 164–70
Coccurello R, Caprioli A, Ghirardi O, et al. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl) 2006; 186(4): 561–71
Albaugh VL, Henry CR, Bello NT, et al. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 2006 Jan; 14(1): 36–51
Ader M, Kim SP, Catalano KJ. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005; 54(3): 862–71
Baptista T, Araujo de Baptista E, Ying Kin NM, et al. Comparative effects of the antipsychotics sulphide or risperidone in rats: I. Bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res 2002; 957(1): 144–51
Kalinichev M, Rourke C, Daniels AJ, et al. Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology (Berl) 2005; 182(2): 220–31
Cope MB, Nagy TR, Fernandez JR, et al. Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes (Lond) 2005; 29(6): 607–14
Kalinichev M, Rourke C, Jones DN. Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine. Behav Pharmacol 2006; 17(3): 289–92
Kirk SL, Cahir M, Reynolds GP. Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus. J Psychopharmacol 2006; 20(4): 577–9
Baptista T, La Cruz A, Mendoza S, et al. Endocrine and metabolic abnormalities involved in the obesity associated to typical antipsychotic drug administration. Pharmacopsychiatry 2001; 34: 223–31
Fadel J, Bubser M, Deutch AY. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 2002; 22(15): 6742–6
Murashita M, Kusumi I, Inoue T, et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 2005; 30(1): 106–10
Birkas Kovats D, Palik E, Faludi G, et al. Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics. Neuropsychopharmacol Hung 2005; 7(3): 132–9
Murashita M, Inoue T, Kusumi I, et al. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry Clin Neurosci 2007; 61(1): 54–8
Togo T, Hasegawa K, Miura S, et al. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology (Berl) 2004; 172(2): 230–2
Palik E, Birkas KD, Faludi G, et al. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 2005; 68Suppl. 1: S60–4
Theisen FM, Gebhardt S, Bromel T, et al. A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 2005; 12(10): 1411–6
Sporn AL, Bobb AJ, Gogtay N, et al. Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. J Am Acad Child Adolesc Psychiatry 2005; 44(9): 925–33
Hosojima H, Togo T, Odawara T, et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 2006; 20(1): 75–9
Rasgon NL, Reynolds MF, Elman S, et al. Longitudinal evaluation of reproductive function in women treated for bipolar disorder. J Affect Disord 2005; 89: 217–25
Baptista T, Reyes D, Hernández L. Antipsychotic drugs and reproductive hormones: relationship with body weight regulation. Pharmacol Biochem Behav 1999; 62: 409–17
Bergemann N, Mundt C, Parzer P, et al. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res 2005; 73: 357–66
Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacol 2003; 28: 519–26
Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci 2000; 68: 29–39
Eder U, Mangweth B, Ebenbichler C, et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 2001; 158: 1719–22
Baptista T, Araujo de Baptista E, Beaulieu S, et al. Comparative effects of sulpiride or risperidone in rats. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1305–11
Vestri HS, Maianu L, Moellering DR, et al. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacol 2007; 32: 765–72
Sharpe JK, Byrne NM, Stedman TJ, et al. Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication. J Am Diet Assoc 2005; 105(4): 612–5
Sharpe JK, Stedman TJ, Byrne NM, et al. Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry 2006; 40(9): 810–4
Virkkunen M, Wahlbeck K, Rissanen A, et al. Decrease of energy expenditure causes weight increase in olanzapine treatment: a case study. Pharmacopsychiatry 2002; 35(3): 124–6
Graham KA, Perkins DO, Edwards LJ, et al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005; 162(1): 118–23
Fan X, Anderson EJ, Copeland PM, et al. Higher fasting insulin is associated with increased resting expenditure in nondiabetic schizophrenia patients. Biol Psychiatry 2006; 60(12): 1372–7
Monda M, Viggiano A, Viggiano A, et al. Clozapine blocks sympathetic and thermogenic reactions induced by orexin A in rats. Physiol Res 2004; 53(5): 507–13
Monda M, Viggiano A, Viggiano A, et al. Quetiapine lowers sympathetic and hyperthermic reactions due to cerebral injection of orexin A. Neuropeptides 2006 Oct; 40(5): 357–63
Olajossy-Hilkesberger L, Godlewska B, Marmurowska-Michalowskal H, et al. Antipsychotic-induced weight gain: pharmacogenetic studies. Psychiatr Pol 2006; 40(5): 1009–20
Muller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006; 7(6): 863–87
Ruano G, Goethe JW, Caley C, et al. Physiogenomic comparison of weight profiles of olanzapine-and risperidone-treated patients. Mol Psychiatry 2007; 12(5): 474–82
Bray GA. Noradrenergic, serotonergic, antiepileptic and herbal drugs. In: Hofbauer KG, Keller U, Boss O, editors. Pharmacotherapy of obesity. Boca Raton (FL): CRC Press, 2004: 267–84
Anghelescu I, Klawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain. J Clin Psychopharmacol 2000; 20(6): 716–7
Carpenter LL, Schecter JM, Sinischalchi J, et al. A case series describing orlistat use in patients on psychotropic medications. Med Health R I 2004; 87(12): 375–7
Pavlovic ZM. Orlistat in the treatment of clozapine-induced hyperglycemia and weight [letter]. Eur Psychiatry 2005; 20(7): 520
Sacchetti E, Guarneri L, Bravi D. H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 2000; 48(2): 167–8
Pae CU, Kim JJ, Lee KU, et al. Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. Hum Psychopharmacol 2003; 18(6): 453–6
Cavazzoni P, Tanaka Y, Roychowdhury SM, et al. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2003; 13(2): 81–5
Atmaca M, Kuloglu M, Tezcan E. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine induced weight gain. Human Psychopharmacol 2003; 18: 457–61
Atmaca M, Kuloglu M, Tezcan E, et al. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Human Psychopharmacol 2004; 19: 37–40
Assuncao SS, Ruschel SI, Rosa Lde C, et al. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Rev Bras Psiquiatr 2006; 28(4): 270–6
López-Mato A, Rovner J, Illa G, et al. Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration. Vertex 2003; 14(52): 85–96
Poyurovsky M, Tal V, Maayan R, et al. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol 2004; 14(4): 332–6
Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine in patients with schizophrenia. Schizophr Res 2006; 82(1): 115–7
Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 2002; 159: 1058–60
Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004; 65: 766–71
Poyurovsky M, Isaacs I, Fuchs C, et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 297–302
Poyurovsky M, Fuchs C, Pashinian A. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology 2007; 192(3): 441–8
Baptista T, Martinez J, Lacruz A. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006; 51(3): 192–6
Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive fist episode schizophrenia patients: a double blind placebo-controlled study. Am J Psychiatry 2008; 165: 352–8
Ko YH, Joe SH, Kim SH. Topiramate as an adjunctive treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 2005; 28(4): 169–75
Nickel MK, Nickel C, Muehlbacher M, et al. Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005; 25(3): 211–7
Bustillo JR, Lauriello J, Parker K, et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacol 2003; 28: 527–9
Henderson DC, Copeland PM, Daley TB, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005; 162: 954–62
Henderson DC, Fan X, Copeland PM, et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 2007; 115(2): 101–5
Borovicka MC, Fuller MA, Konicki E, et al. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. Clin Psychiatry 2002; 63(4): 345–8
Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 2005; 15: 13–21
Graham KA, Gu H, Lieberman JA. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 2005; 162: 1744–6
Klein DJ, Cottingham EM, Sorter M, et al. A randomized, double-blind, placebo-controlled trial of metformin in treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006; 163(12): 2072–9
Baptista T, Rangel N, Fernandez V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007; 93: 99–108
Wu RR, Zhao JP, Jin H, et al. Life style intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008; 299: 185–93
Baptista T, Uzcátegui E, Rangel N, et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 2008; 159(1–2): 250–3
Baptista T, Rangel N, ElFakih Y. Rosiglitazone in the treatment of weight gain and metabolic dysfunction during olanzapine administration: a double-blind, placebo controlled pilot study. Society of Neuroscience Annual Meeting; 2007 Nov 3–7; San Diego (CA)
Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss [letter]. Can J Psychiatry 2000; 45(2): 198
Lessig MC, Shapira NA, Murphy TK. Topiramate for reversing atypical antipsychotic weight gain [letter]. J Am Acad Child Adolesc Psychiatry 2001; 40(12): 1364
Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia [letter]. J Clin Psychiatry 2002; 63(11): 1045
Lin YH, Liu CY, Hsiao MC. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin Neurosci 2005; 59(5): 613–5
Canitano R. Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev 2005; 27(3): 228–32
Vieta E, Sanchez-Moreno J, Goikolea JM, et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol 2004; 24(4): 374–8
Poyurovsky M, Pashinian A, Levi A, et al. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol 2005; 20(2): 101–3
Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol 2001; 11(2): 181–2
Bahk WM, Lee KU, Chae JH, et al. Open label study of the effect of amantadine on weight gain induced by olanzapine. Psychiatry Clin Neurosci 2004; 58(2): 163–7
Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002; 159(4): 655–7
Chen CH, Chiu CC, Huang MC, et al. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. Epub 2007 Nov 17
Baptista T, Kin NM, Beaulieu S. Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions. Clin Pharmacokinet 2004; 43(1): 1–15
Aminoff MJ. Pharmacotherapy of Parkinson disease and other movement disorders. In: Katsung BG, editor. Basic and clinical pharmacology. New York: McGraw-Hill Companies, Inc., 2001: 523–38
Deleu D, North MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002; 41: 261–309
Keck Jr PE, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry 2002; 63 Suppl. 4: 3–11
Stenlöf K, Rössner S, Vercruysse F, et al. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab 2007; 9(3): 360–8
Migliardi G, D’Arrigo C, Santoro V, et al. Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. ClinNeuropharmacol 2007; 30(2): 107–13
Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19: 299–320
Abolfathi Z, Couture J, Vallee F, et al. A pilot study to evaluate the pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions. J Pharm Pharm Sci 2004; 7(3): 345–9
Park JY, Kim KA, Park PW, et al. Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study. Clin Ther 2004; 26(12): 2092–101
Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Practice 1999; 49: 871–4
Bijl D. The serotonin syndrome. Neth J Med 2004; 62(9): 309–13
Baptista T, Sandia I, LaCruz A, et al. Insulin counter-regulatory factors, fibrinogen and c-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int Clin Psychopharmacol 2007; 22(2): 69–76
Basit AW, Newton JM, Lacey LF. Susceptibility of the H2-receptor antagonists cimetidine, famotidine, and nizatidine, to metabolism by the gastrointestinal microflora. Int J Pharm 2002; 237: 23–33
Furuta S, Kamada E, Suzuky T, et al. Inhibition of drug metabolism in human liver microsomas by nizatidine, cimetidi e and omeprazole. Xenoviotica 2001; 31: 1–10
Food and Drug Administration. Guidance for the clinical evaluationof weight control drugs. Rockville (MD): Food and DrugAdministration, 1996]
European Agency for the Evaluation of Medicinal ProductsCommittee for Proprietary Medicinal Products (CPMP). Clinicalinvestigation of drugs used in weight control. London: The European Agency for the Evaluation of Medicinal Products, 1997
Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369(9555): 71–7
Kalucky RS. Drug-induced weight gain. Drugs 1980; 19: 268–78
Kinon BJ, Kaiser CJ, Ahmed S, et al. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005; 25(3): 255–8
Acknowledgements
This article was supported by Fondo Nacional de Ciencia, Tecnología e Investigación (FONACIT), Caracas, Venezuela, grant no. 2005-000-384. The authors have no other conflicts of interest that are directly relevant to the content of this review. The authors particularly thank Françoise Meyer for her editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Baptista, T., ElFakih, Y., Uzcátegui, E. et al. Pharmacological Management of Atypical Antipsychotic-Induced Weight Gain. CNS Drugs 22, 477–495 (2008). https://doi.org/10.2165/00023210-200822060-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-200822060-00003